(array CGH) using com¬mercially available array-CGH slides (MACArray Karyo 1440 BAC-chip; Macrogen, Seoul, Korea). We also investigated the genotype-phenotype correlation, especially focused on genomic deletion size, final adult height, and bone mineral density (BMD).
Introduction
Deletion 22q11.2 (22q11.2DS) is the most common microdeletion syndrome in human, with a minimum prevalence rate of one in 4,000 live births. 1, 2) Nomenclatures for 22q11.2DS include velocardiofacial syndrome, DiGeorge syndrome, and CATCH22 (cardiac anomaly, abnormal face, thymic hypoplasia, cleft palate, hypocalcemia) syndrome. These various nomenclatures reflect the myriad of clinical features. [3] [4] [5] [6] Short stature is one of the most common clinical features of 22q11.2DS. However, it is unclear whether short stature is an intrinsic manifestation of this syndrome, or whether it is secondary to other clinical features. 
Discussion
Although short stature is one of the most common clinical features of 22q11.2DS, the mechanism is unclear. In infancy, the growth pattern in the 22q11.2DS is slow. Several studies reported final adult heights are usually in the normal range. 3, 10) However, an analysis of the growth charts from 188 patients reported that adults with this syndrome remained below the 2nd percentile for the normal population. Average heights for male and female adults were 167.2 cm and 158.2 cm, respectively. 8) Another paper reported that final adult heights were 166 cm and 152 cm, respectively. 7) Two patients of this report were shorter than these reference values. These two cases had low BMD with or without hypoparathyroidism and hypocalcemia. Bone mass and metabolism of the patients with 22q11.2DS are almost unknown. Stagi et al. 11) reported that patients with 22q11.2DS had reduced bone mass measured by bone mineral apparent density. The reduction of bone mass worsened with age in adults. The authors explained that lower bone mass was probably due to reduced bone modeling during childhood, which would result in a reduced peak bone mass, posing a significant risk of impaired bone mass in adulthood. 11) Hypoparathyroidism and hypocalcemia are also frequent manifestations in 22q11.2DS, although are the insufficient cause of reduced BMD. Post-surgical hypopatathyroidism as well as idiopathic hypoparathyroidism increases BMD. [12] [13] [14] Therefore, the causes of reduced bone mass in 22q11.2DS may be multifocal. Previous studies reported 50% to 80% of the variance in bone mass is genetically determined. [15] [16] [17] A Caucasian genome wide linkage study suggested lumbar spine BMD is affected by chromosome 22q11-12. 18) Therefore, deletion of 22q11 may be an important factor of reduced BMD. The TBX 1 is most important factor of pathogenesis of 22q11.2DS. TBX 1 is expressed at cardiac outflow, pharyngeal mesenchyme, and endodermal pouch. Therefore, deletion of this gene could lead to most of the phenotypes of 22q11.2DS6. TBX 1 is also expressed in the sclerotome, which differentiates to the spinal column. 19) Fulcoli et al. 20) reported that TBX 1 contributes to the BMP/Smad1 pathway, which could affect osteoblast differentiation. These results suggest TBX 1 could be a factor of reduced BMD of 22q11.2DS. The third case in this paper was of normal stature and had normal BMD. Her deletion site did not include the TBX 1 .
The association TBX 1 and short stature is already known however the mechanism has not been understood. We reviewed all common gene of two cases with short stature and low BMD. There was no gene which has the possibility of direct effect to bone metabolism except TBX 1 . Here, we report only three cases, so it may be incidental.
Nevertheless, the possibility of the influence of TBX 1 to bone metabolism is interesting. Short stature could be a result of low bone mass, influenced by the TBX 1 
